171 related articles for article (PubMed ID: 14574332)
21. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
23. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
24. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
[TBL] [Abstract][Full Text] [Related]
25. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
Osterborg A; Henriksson L; Mellstedt H
Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
[TBL] [Abstract][Full Text] [Related]
26. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
[TBL] [Abstract][Full Text] [Related]
27. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
28. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
Lim SH; Bailey-Wood R
Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
[TBL] [Abstract][Full Text] [Related]
29. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC).
Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
Ann Oncol; 2008 Jun; 19(6):1172-9. PubMed ID: 18272909
[TBL] [Abstract][Full Text] [Related]
30. Idiotype vaccination of myeloma patients after chemotherapy.
Massaia M
Acta Oncol; 2000; 39(7):807-8. PubMed ID: 11145437
[No Abstract] [Full Text] [Related]
31. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
[TBL] [Abstract][Full Text] [Related]
32. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
Gravelle M; Ochi A
J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
Zahradova L; Mollova K; Ocadlikova D; Kovarova L; Adam Z; Krejci M; Pour L; Krivanova A; Sandecka V; Hajek R
Neoplasma; 2012; 59(4):440-9. PubMed ID: 22489700
[TBL] [Abstract][Full Text] [Related]
34. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
[TBL] [Abstract][Full Text] [Related]
35. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
Timmerman JM; Vose JM; Czerwinski DK; Weng WK; Ingolia D; Mayo M; Denney DW; Levy R
Leuk Lymphoma; 2009 Jan; 50(1):37-46. PubMed ID: 19125383
[TBL] [Abstract][Full Text] [Related]
36. Tumor idiotype vaccines. VI. Synergistic anti-tumor effects with combined "internal image" anti-idiotypes and chemotherapy.
Chen JJ; Saeki Y; Shi LF; Köhler H
J Immunol; 1989 Aug; 143(3):1053-7. PubMed ID: 2745974
[TBL] [Abstract][Full Text] [Related]
37. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
Stritzke J; Zunkel T; Steinmann J; Schmitz N; Uharek L; Zeis M
Br J Haematol; 2003 Jan; 120(1):27-35. PubMed ID: 12492573
[TBL] [Abstract][Full Text] [Related]
39. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
[TBL] [Abstract][Full Text] [Related]
40. Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Holman PR; Costello C; deMagalhaes-Silverman M; Corringham S; Castro J; Ball ED
Biol Blood Marrow Transplant; 2012 Feb; 18(2):257-64. PubMed ID: 21736867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
